AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.